Engage Early With Regulators On Complex Trial Designs, Sponsors Told
Accelerated And Conditional Approvals Will Also Be Key
New recommendations from UK academics, regulators and industry highlight the importance of proper planning when clinical studies are being prepared in areas such as oncology.
You may also be interested in...
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.
The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.